Mössner, Rotraut

[["dc.bibliographiccitation.firstpage","989"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","The Journal of Dermatology"],["dc.bibliographiccitation.lastpage","997"],["dc.bibliographiccitation.volume","47"],["dc.contributor.author","Kromer, Christian"],["dc.contributor.author","Loewe, Emilia"],["dc.contributor.author","Schaarschmidt, Marthe‐Lisa"],["dc.contributor.author","Pinter, Andreas"],["dc.contributor.author","Gerdes, Sascha"],["dc.contributor.author","Celis, Daniel"],["dc.contributor.author","Poortinga, Sietske"],["dc.contributor.author","Wilsmann‐Theis, Dagmar"],["dc.contributor.author","Mössner, Rotraut"],["dc.date.accessioned","2021-04-14T08:24:11Z"],["dc.date.available","2021-04-14T08:24:11Z"],["dc.date.issued","2020"],["dc.description.abstract","Abstract Acrodermatitis continua of Hallopeau (ACH) is a rare chronic inflammatory skin disease. Treatment is extremely challenging and mostly based on empirics as there is only scarce evidence from case reports and few small case series. In this retrospective study, patients with ACH treated at five university medical centers were analyzed according to patient and disease characteristics and treatment experience. We identified 39 patients with ACH with a mean age of 54.4 years at onset, of whom 22 (56.4%) were female. A total of 115 systemic treatment courses were analyzed with methotrexate as the most common therapy (27.0%). Overall, effectiveness of systemic treatments was low (excellent response rate: 14.8%). Among non‐biologics, excellent response was noted in 21.1% (4/19) of treatment courses with methotrexate, followed by acitretin (13.3%; 2/15). Among biologics, guselkumab (excellent response: 100%; 2/2), secukinumab (excellent response: 42.9%; 3/7) and adalimumab (excellent response: 20.0%; 2/10) were most efficacious. The median drug survival was 7.0 months and did not differ significantly between the subgroup of non‐biologic and biologic therapies. To our knowledge, this is the largest case series in ACH investigating patient characteristics and treatment outcomes. Based on our treatment experience, we suggest a treatment algorithm starting with acitretin or methotrexate as first‐line therapy, followed by biologics. Cyclosporin may be used for short‐term control. However, none of the applied systemic therapies yielded satisfying efficacy in our cohort. In patients with primary non‐response, switch of treatment should be evaluated timely on an individual basis, considering possible irreversible disease complications such as nail loss. More research with prospective design is needed to further evaluate traditional and also particularly newer antipsoriatic drugs in ACH."],["dc.identifier.doi","10.1111/1346-8138.15466"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/81196"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1346-8138"],["dc.relation.issn","0385-2407"],["dc.rights","This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made."],["dc.title","Treatment of acrodermatitis continua of Hallopeau: A case series of 39 patients"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1441"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],["dc.bibliographiccitation.lastpage","1452"],["dc.bibliographiccitation.volume","20"],["dc.contributor.affiliation","Faverio, Kristin; 1\r\nDepartment of Dermatology and Phlebology\r\nVivantes Klinikum im Friedrichshain\r\nBerlin Germany"],["dc.contributor.affiliation","Peitsch, Wiebke K.; 1\r\nDepartment of Dermatology and Phlebology\r\nVivantes Klinikum im Friedrichshain\r\nBerlin Germany"],["dc.contributor.affiliation","Görig, Tatiana; 3\r\nDepartment of Medical Informatics\r\nBiometry and Epidemiology\r\nFriedrich‐Alexander‐University of Erlangen‐Nuremberg\r\nErlangen Germany"],["dc.contributor.affiliation","Schneider‐Burrus, Sylke; 4\r\nCenter for Dermatosurgery\r\nHavelklinik\r\nBerlin Germany"],["dc.contributor.affiliation","Benzel, Friderike; 1\r\nDepartment of Dermatology and Phlebology\r\nVivantes Klinikum im Friedrichshain\r\nBerlin Germany"],["dc.contributor.affiliation","Goebeler, Matthias; 5\r\nDepartment of Dermatology\r\nVenereology and Allergology\r\nUniversity Hospital Würzburg\r\nWürzburg Germany"],["dc.contributor.affiliation","Schummer, Patrick; 5\r\nDepartment of Dermatology\r\nVenereology and Allergology\r\nUniversity Hospital Würzburg\r\nWürzburg Germany"],["dc.contributor.affiliation","Badran, Alaa; 5\r\nDepartment of Dermatology\r\nVenereology and Allergology\r\nUniversity Hospital Würzburg\r\nWürzburg Germany"],["dc.contributor.affiliation","Schaarschmidt, Marthe‐Lisa; 6\r\nDepartment of Dermatology\r\nVenereology and Allergology\r\nUniversity Medical Center Mannheim\r\nHeidelberg University\r\nMannheim Germany"],["dc.contributor.affiliation","Harth, Wolfgang; 7\r\nDepartment of Dermatology and Allergology\r\nVivantes Klinikum Spandau\r\nBerlin Germany"],["dc.contributor.affiliation","Mössner, Rotraut; 8\r\nDepartment of Dermatology\r\nVenereology and Allergology\r\nUniversity Medical Center Göttingen\r\nGöttingen Germany"],["dc.contributor.author","Faverio, Kristin"],["dc.contributor.author","Peitsch, Wiebke K."],["dc.contributor.author","Görig, Tatiana"],["dc.contributor.author","Schneider‐Burrus, Sylke"],["dc.contributor.author","Benzel, Friderike"],["dc.contributor.author","Goebeler, Matthias"],["dc.contributor.author","Schummer, Patrick"],["dc.contributor.author","Badran, Alaa"],["dc.contributor.author","Schaarschmidt, Marthe‐Lisa"],["dc.contributor.author","Harth, Wolfgang"],["dc.contributor.author","Kromer, Christian"],["dc.contributor.author","Mössner, Rotraut"],["dc.date.accessioned","2022-12-01T08:31:11Z"],["dc.date.available","2022-12-01T08:31:11Z"],["dc.date.issued","2022"],["dc.date.updated","2022-11-27T10:10:51Z"],["dc.description.abstract","Summary\r\n\r\nBackground and Objectives\r\nTreatment options for moderate‐to‐severe hidradenitis suppurativa (HS) comprise antibiotics, biologics, and different surgical methods. These approaches differ substantially regarding the treatment process, success rates, and adverse events. However, information on patient preferences for HS therapies is hitherto scarce. Our aim was to assess patient preferences for medicamentous and surgical treatment of HS with conjoint analysis.\r\n\r\n\r\nPatients and Methods\r\nIn this cross‐section study, computerized discrete choice experiments were used to quantify patient preferences for HS therapies decomposed into treatment modality (tablets, subcutaneous injections, surgery with secondary‐intention healing or primary closure), probability of sustained therapeutic success, probability of mild or severe adverse events, and duration of treatment or wound healing.\r\n\r\n\r\nResults\r\nAveraged over the cohort (n  =  216 patients with HS), sustained therapeutic success was considered as most important (Relative Importance Score [RIS]: 36.2), followed by the treatment modality (RIS: 24.0), and duration of treatment/wound healing (RIS: 19.9), whereas mild or severe adverse events (RIS: 10.7 or 9.3) were regarded as less relevant. Patients preferred tablets, followed by subcutaneous injections, and disliked surgery with primary closure. Preferences differed significantly dependent on age and affected body regions.\r\n\r\n\r\nConclusions\r\nAwareness of patient preferences is essential for patient‐centered care in HS."],["dc.identifier.doi","10.1111/ddg.14886"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/118101"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-621"],["dc.relation.eissn","1610-0387"],["dc.relation.issn","1610-0379"],["dc.rights","This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made."],["dc.rights.uri","http://creativecommons.org/licenses/by-nc-nd/4.0/"],["dc.title","Patient Preferences in Hidradenitis Suppurativa (APProach‐HS): a discrete choice experiment"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","843"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Vaccines"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Kromer, Christian"],["dc.contributor.author","Wellmann, Phoebe"],["dc.contributor.author","Siemer, Ralf"],["dc.contributor.author","Klein, Selina"],["dc.contributor.author","Mohr, Johannes"],["dc.contributor.author","Pinter, Andreas"],["dc.contributor.author","Wilsmann-Theis, Dagmar"],["dc.contributor.author","Mössner, Rotraut"],["dc.date.accessioned","2021-10-01T09:58:33Z"],["dc.date.available","2021-10-01T09:58:33Z"],["dc.date.issued","2021"],["dc.description.abstract","The risk of developing severe complications from an influenza virus infection is increased in patients with chronic inflammatory diseases such as psoriasis (PsO) and atopic dermatitis (AD). However, low influenza vaccination rates have been reported. The aim of this study was to determine vaccination rates in PsO compared to AD patients and explore patient perceptions of vaccination. A multicenter cross-sectional study was performed in 327 and 98 adult patients with PsO and AD, respectively. Data on vaccination, patient and disease characteristics, comorbidity, and patient perceptions was collected with a questionnaire. Medical records and vaccination certificates were reviewed. A total of 49.8% of PsO and 32.7% of AD patients were vaccinated at some point, while in season 2018/2019, 30.9% and 13.3% received an influenza vaccination, respectively. There were 96.6% and 77.6% of PsO and AD patients who had an indication for influenza vaccination due to age, immunosuppressive therapy, comorbidity, occupation, and/or pregnancy. Multivariate regression analysis revealed higher age (p < 0.001) and a history of bronchitis (p = 0.023) as significant predictors of influenza vaccination in PsO patients. Considering that most patients had an indication for influenza vaccination, the rate of vaccinated patients was inadequately low."],["dc.description.abstract","The risk of developing severe complications from an influenza virus infection is increased in patients with chronic inflammatory diseases such as psoriasis (PsO) and atopic dermatitis (AD). However, low influenza vaccination rates have been reported. The aim of this study was to determine vaccination rates in PsO compared to AD patients and explore patient perceptions of vaccination. A multicenter cross-sectional study was performed in 327 and 98 adult patients with PsO and AD, respectively. Data on vaccination, patient and disease characteristics, comorbidity, and patient perceptions was collected with a questionnaire. Medical records and vaccination certificates were reviewed. A total of 49.8% of PsO and 32.7% of AD patients were vaccinated at some point, while in season 2018/2019, 30.9% and 13.3% received an influenza vaccination, respectively. There were 96.6% and 77.6% of PsO and AD patients who had an indication for influenza vaccination due to age, immunosuppressive therapy, comorbidity, occupation, and/or pregnancy. Multivariate regression analysis revealed higher age (p < 0.001) and a history of bronchitis (p = 0.023) as significant predictors of influenza vaccination in PsO patients. Considering that most patients had an indication for influenza vaccination, the rate of vaccinated patients was inadequately low."],["dc.description.sponsorship","Novartis Pharma"],["dc.identifier.doi","10.3390/vaccines9080843"],["dc.identifier.pii","vaccines9080843"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/90088"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-469"],["dc.publisher","MDPI"],["dc.relation.eissn","2076-393X"],["dc.rights","https://creativecommons.org/licenses/by/4.0/"],["dc.title","Influenza Vaccination in Psoriatic Patients—Epidemiology and Patient Perceptions: A German Multicenter Study (Vac-Pso)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Vaccines"],["dc.bibliographiccitation.volume","10"],["dc.contributor.affiliation","Wellmann, Phoebe; 1Department of Dermatology, University Medical Center Göttingen, 37075 Göttingen, Germany; phoebe.wellmann@stud.uni-goettingen.de (P.W.); christian.kromer@med.uni-goettingen.de (C.K.); johannes.mohr@med.uni-goettingen.de (J.M.); undine.lippert@med.uni-goettingen.de (U.L.)"],["dc.contributor.affiliation","Kromer, Christian; 1Department of Dermatology, University Medical Center Göttingen, 37075 Göttingen, Germany; phoebe.wellmann@stud.uni-goettingen.de (P.W.); christian.kromer@med.uni-goettingen.de (C.K.); johannes.mohr@med.uni-goettingen.de (J.M.); undine.lippert@med.uni-goettingen.de (U.L.)"],["dc.contributor.affiliation","Siemer, Ralf; 2Faculty of Mathematics and Computer Science, University of Göttingen, 37073 Göttingen, Germany; ralf.siemer@stud.uni-goettingen.de"],["dc.contributor.affiliation","Klein, Selina; 3Department of Dermatology and Allergy, University Bonn, 53127 Bonn, Germany; selina.klein@ukbonn.de (S.K.); dagmar.wilsmann-theis@ukbonn.de (D.W.-T.)"],["dc.contributor.affiliation","Mohr, Johannes; 1Department of Dermatology, University Medical Center Göttingen, 37075 Göttingen, Germany; phoebe.wellmann@stud.uni-goettingen.de (P.W.); christian.kromer@med.uni-goettingen.de (C.K.); johannes.mohr@med.uni-goettingen.de (J.M.); undine.lippert@med.uni-goettingen.de (U.L.)"],["dc.contributor.affiliation","Lippert, Undine; 1Department of Dermatology, University Medical Center Göttingen, 37075 Göttingen, Germany; phoebe.wellmann@stud.uni-goettingen.de (P.W.); christian.kromer@med.uni-goettingen.de (C.K.); johannes.mohr@med.uni-goettingen.de (J.M.); undine.lippert@med.uni-goettingen.de (U.L.)"],["dc.contributor.affiliation","Pinter, Andreas; 4Department of Dermatology, Venerology and Allergology, University of Frankfurt, 60590 Frankfurt am Main, Germany; andreas.pinter@kgu.de"],["dc.contributor.affiliation","Wilsmann-Theis, Dagmar; 3Department of Dermatology and Allergy, University Bonn, 53127 Bonn, Germany; selina.klein@ukbonn.de (S.K.); dagmar.wilsmann-theis@ukbonn.de (D.W.-T.)"],["dc.contributor.affiliation","Mössner, Rotraut; 1Department of Dermatology, University Medical Center Göttingen, 37075 Göttingen, Germany; phoebe.wellmann@stud.uni-goettingen.de (P.W.); christian.kromer@med.uni-goettingen.de (C.K.); johannes.mohr@med.uni-goettingen.de (J.M.); undine.lippert@med.uni-goettingen.de (U.L.)"],["dc.contributor.author","Wellmann, Phoebe"],["dc.contributor.author","Kromer, Christian"],["dc.contributor.author","Siemer, Ralf"],["dc.contributor.author","Klein, Selina"],["dc.contributor.author","Mohr, Johannes"],["dc.contributor.author","Lippert, Undine"],["dc.contributor.author","Pinter, Andreas"],["dc.contributor.author","Wilsmann-Theis, Dagmar"],["dc.contributor.author","Mössner, Rotraut"],["dc.date.accessioned","2022-07-11T06:54:31Z"],["dc.date.available","2022-07-11T06:54:31Z"],["dc.date.issued","2022-06-23"],["dc.date.updated","2022-07-08T13:34:06Z"],["dc.description.abstract","While suboptimal pneumococcal vaccination rates have been reported in immunosuppressed patients with rheumatic diseases, data for patients with psoriasis (PsO) or atopic dermatitis (AD) are scarce. Pneumococcal vaccination in Germany is recommended in patients with certain comorbidities, immunosuppression, and/or aged 60 years or above. The aim of this multicenter cross-sectional study was to investigate the pneumococcal vaccination rate in patients with PsO compared to patients with AD and to evaluate patient perceptions. All patients completed a questionnaire on vaccination status and perceptions, patient and disease characteristics, as well as comorbidity. Medical records and vaccination certificates were reviewed. Over the whole cohort (n = 327 PsO (41.9% female), n = 98 AD (42.9% female)), 83.8% and 42.9% of PsO and AD patients, respectively, had an indication for pneumococcal vaccination due to immunosuppressive treatment. The pneumococcal vaccination rate was 14.4% and 10.2% in PsO and AD patients, respectively. The vaccination rate depended significantly on age, working status and presence of psoriatic arthritis. The most common reason for nonvaccination was lacking recommendation by physicians. Higher awareness, particularly for vaccination indication due to immunosuppression among dermatologists, general physicians, and patients, is warranted."],["dc.description.sponsorship","Novartis Pharma"],["dc.identifier.doi","10.3390/vaccines10071005"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/112431"],["dc.language.iso","en"],["dc.relation.eissn","2076-393X"],["dc.rights","CC BY 4.0"],["dc.title","Low Pneumococcal Vaccination among Patients with Psoriasis in Germany: Results from Vac-Pso"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]